These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 14470436)

  • 1. [Anti-poliomyelitis vaccination with inactivated virus (Lepine vaccine). Effect of the booster injection on immunization].
    MARTIN R; ROGER F; DAMAS JP; ROGER A; JUILLARD P
    Bull Acad Natl Med; 1961 Nov 21-28; 145():664-73. PubMed ID: 14470436
    [No Abstract]   [Full Text] [Related]  

  • 2. [2 1/2 Years of antipoliomyelitis vaccination (Lepine vaccine) at the Institut Pasteur hospital. Immunological results. Significance of the booster injection].
    MARTIN R; ROGER F; DAMAS JP; ROGER A
    Ann Inst Pasteur (Paris); 1959 Dec; 97():757-79. PubMed ID: 14421731
    [No Abstract]   [Full Text] [Related]  

  • 3. [Antibody response of infants to a "booster" dose of the Salk type of poliomyelitis vaccine given from 5 to 6 months after early primary immunization].
    MORRONE G; NUNZIATA B
    Pediatria (Napoli); 1961; 69():851-6. PubMed ID: 14476315
    [No Abstract]   [Full Text] [Related]  

  • 4. [Study of poliomyelitis antibodies in Lorraine before, during and after vaccination with the Lepine vaccine in a group of subjects observed systematically].
    de LAVERGNE ; GERBAUT P; LORRAIN J; POLJE F; GILGENKRANTZ ; LE MOYNE MT; MATHIEU J
    Ann Inst Pasteur (Paris); 1959 Dec; 97():848-54. PubMed ID: 14414644
    [No Abstract]   [Full Text] [Related]  

  • 5. [Effects of aluminum hydroxide on the immunizing properties of inactivated poliomyelitis vaccine].
    HAAS R; DOSTAL V; SAUTHOFF R
    Klin Wochenschr; 1955 Dec; 33(45-46):1082-4. PubMed ID: 13287015
    [No Abstract]   [Full Text] [Related]  

  • 6. Studies onthe development of natural immunity to poliomyelitis in Louisiana. IV. Natural infections with polioviruses following immunization with a formalin-inactivated vaccine.
    GELFAND HM; LeBLANC DR; POTASH L; FOX JP
    Am J Hyg; 1959 Nov; 70():312-27. PubMed ID: 13827182
    [No Abstract]   [Full Text] [Related]  

  • 7. Immunization of infants with formalinized poliomyelitis vaccine (Salk type).
    SPIGLAND I; GOLDBLUM N
    Pediatrics; 1960 May; 25():812-21. PubMed ID: 13833339
    [No Abstract]   [Full Text] [Related]  

  • 8. [Poliomyelitis vaccination. Value of a booster injection].
    MARTIN R; DAMAS JP
    Rev Med Fr; 1960 Jan; 41():27-32. PubMed ID: 24546182
    [No Abstract]   [Full Text] [Related]  

  • 9. Present status of immunization against poliomyelitis (Salk vaccine versus living, attenuated virus).
    WEISS C
    J Albert Einstein Med Cent (Phila); 1956 Sep; 4(4):159-60. PubMed ID: 13357446
    [No Abstract]   [Full Text] [Related]  

  • 10. Immunization against poliomyelitis with a trivalent oral vaccine.
    COX HR; CABASSO VJ; EMBIL J; MARKHAM FS; MOSES MJ; MOYER AW; ROCA-GARCIA M; RUEGSEGGER JM
    Pathol Microbiol (Basel); 1961; 24(Suppl)():61-72. PubMed ID: 13696125
    [No Abstract]   [Full Text] [Related]  

  • 11. [Immunologic response to a booster injection following an early vaccination against poliomyelitis].
    BUTLER N
    Rev Immunol Ther Antimicrob; 1960; 24():249-50. PubMed ID: 13806504
    [No Abstract]   [Full Text] [Related]  

  • 12. Immunization of man against poliomyelitis with attenuated preparations of living virus.
    KOPROWSKI H
    Ann N Y Acad Sci; 1955 Sep; 61(4):1039-49. PubMed ID: 13340613
    [No Abstract]   [Full Text] [Related]  

  • 13. [Immunization with live polio vaccine].
    VODOPIJA I
    Lijec Vjesn; 1962 Jun; 84():545-51. PubMed ID: 13926382
    [No Abstract]   [Full Text] [Related]  

  • 14. Response of infants to a third dose of poliomyelitis vaccine given 10 to 12 months after primary immunization.
    PERKINS FT; YETTS R; GAISFORD W
    Br Med J; 1959 Mar; 1(5123):680-2. PubMed ID: 13629087
    [No Abstract]   [Full Text] [Related]  

  • 15. Antibody response and survival following booster injections of poliomyelitis (killed-virus) vaccine.
    BATSON R; CHRISTIE A; CHEATHAM WJ; MICHAL ML; SLEIGHT GW
    Pediatrics; 1962 Jan; 29():116-20. PubMed ID: 13865768
    [No Abstract]   [Full Text] [Related]  

  • 16. The relationship between specific skin reaction and neutralizing antibody titers in the young infant following immunization with poliomyelitis (Salk-type) vaccine.
    MORRONE G; NUNZIATA B
    Ann Paediatr; 1961; 196():389-98. PubMed ID: 13772899
    [No Abstract]   [Full Text] [Related]  

  • 17. [Observations on the immunizing effect of small doses of poliomyelitis vaccine inoculated by intradermal route in adult subjects].
    ROSA A; LA PLACA M
    Riv Ital Ig; 1959; 19():143-8. PubMed ID: 14438768
    [No Abstract]   [Full Text] [Related]  

  • 18. [Current status of active immunization against poliomyelitis. Problems related to active and inactivated vaccines].
    AUERSWALD W; EHRICH C
    Rev Paul Med; 1960 Feb; 56():145-52. PubMed ID: 13795087
    [No Abstract]   [Full Text] [Related]  

  • 19. Persistence of antibody following booster dose of poliomyelitis vaccine.
    WILSON RJ; MOSS GW; JACOBS JP; MACLEOD DR
    Can J Public Health; 1962 Jan; 53():17-21. PubMed ID: 14007415
    [No Abstract]   [Full Text] [Related]  

  • 20. Spotlight on DTPa-HBV-IPV/Hib Vaccine (Infanrix hexa).
    Dhillon S
    BioDrugs; 2010 Oct; 24(5):299-302. PubMed ID: 20795752
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.